upcoming glp-1 drugs New oral drug delivers up to 12% weight loss in 36 weeks A new wave of weight-loss

Description

Most big pharma companies have at least one amylin in development, the most advanced of which is Novo Nordisks CagriSema, a dual amylin/GLP-1 agonist currently under FDA review

The team, led by Po Hien Ear, PhD, measured the expression of GLP-1 receptors and assessed their response to semaglutide treatment in six NEN cell models

In the future, a multidimensional line of evidence is needed to clarify the source of GLP-1RA effects in IBD, including in vitro experiments to confirm direct actions, animal models designed to exclude metabolic interference, and clinical data adjusted for metabolic confounders

This article is republished from The Conversation , a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world